临床发现在一个多民族的成年人乙肝病毒患者人数在丹麦重

StephenW

Clinical findings in a multi-ethnic adult hepatitis B virus patient population in Denmark with emphasis on genotypic characteristics

August 2015, Vol. 50, No. 8 , Pages 1032-1038 (doi:10.3109/00365521.2014.974202)

Nanna-Sophie Brinck-Jensen, Purnima Erichsen, Britta Tarp, Jens Lindberg, Lena H. Kristensen, Mogens Erlandsen, Eskild Petersen, and Peter D. C Leutscher
1Department of Infectious Diseases, Aarhus University Hospital, Skejby, Denmark
2Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark
3Department of Infectious Diseases, Regionshospitalet Herning, Herning, Denmark
4Department of Infectious Diseases, Regionshospitalet Viborg, Viborg, Denmark
5Department of Public Health, Section of Biostatistics, Aarhus University Hospital, Aarhus, Denmark
Correspondence: Peter Christian Derek Leutscher, Department of Infectious Diseases, Brendstrupgaardvej 100, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark. +45 78 45 28 22. [email protected]


Abstract

Objective. Most knowledge about chronic hepatitis B virus (HBV) infection is based upon studies in high-endemic areas with one or two predominant genotype(s). The aim of the study was to describe clinical characteristics of a heterogeneous genotypic HBV patient population in a low-endemic European country. Methods. Data from HBV patients currently followed in a Danish university hospital and affiliated regional clinics were reviewed in accordance to genotype status. Results. Of 540 HBV patients, 462 (86%) were of non-Danish ethnicity originating from 43 different countries. HBV genotype was known in 37% of the patients: A (11%), B (25%), C (25%), D (37%) and E (2%). Logistic regression analysis of pre-treatment data among genotype A-D patients receiving nucleos(t)ide analogue (NA) therapy revealed a decreased HBeAg rate by age (OR = 0.93; CI: 0.89–0.97; p < 0.01) and an increased rate in genotype C patients (OR = 20.5; CI: 3.3–129; p < 0.01). Among untreated patients HBeAg rate was also significantly decreased by age (OR = 0.90 (0.85:0.95; p < 0.0001), whereas the rate was increased in both genotype B and C patients (OR = 7.5; CI: 1.8–30.5; p < 0.01 and OR = 12.2; CI: 3.2–46.6; p < 0.001, respectively). No significant variation was found in HBV DNA level in any of the two groups when adjusting for age, gender, genotype and HBeAg. Increased liver pathology prevalence was, irrespectively of treatment status, associated to age and male gender, but not to any genotype. Conclusion. In this study population, genotype B and C was found associated with higher HBeAg rate but not with increased liver pathology.



Read More: http://informahealthcare.com/doi/abs/10.3109/00365521.2014.974202

StephenW

临床发现在一个多民族的成年人乙肝病毒患者人数在丹麦重点在基因型特征

2015年8月，卷。 50，8号，页1032-1038（DOI：10.3109 / 00365521.2014.974202）

南纳 - 索菲Brinck - 延森，主任Purnima埃里克森，布丽塔不良资产救助计划，延林德伯格，莉娜H.克里斯滕森，莫恩斯Erlandsen，Eskild彼得森，和彼得·ÇLeutscher
教研室传染病，奥胡斯大学医院，Skejby，丹麦
2Diagnostic中心，锡尔克堡地区医院，锡尔克堡，丹麦
3Department传染病，Regionshospitalet海宁，海宁，丹麦
4Department传染病，Regionshospitalet维堡，维堡，丹麦
公共卫生，生物统计科，奥胡斯大学医院，奥尔胡斯，丹麦5Department
函授：彼得·德里克基督教Leutscher，传染科，Brendstrupgaardvej 100，奥胡斯大学医院，Skejby，DK-8200奥尔胡斯N，丹麦。 +45 78 45 28 22 [email protected]


抽象

客观。最知识慢性乙型肝炎病毒（HBV）感染是基于在高流行地区的研究与一个或两个主要基因型（多个）。这项研究的目的是描述在低流行欧洲国家异构基因型的HBV患者群体的临床特征。方法。目前遵循丹麦大学医院从患者的HBV数据和附属区域诊所按照基因型身份审查。结果。 540 HBV患者中，462（86％）是非丹麦种族来自43个不同国家的起源。 HBV基因型被称为在37％的患者：A（11％），B（25％），C（25％），D（37％）和E（2％）。预处理的数据在接受核苷（酸）类似物IDE（NA）基因治疗AD患者Logistic回归分析显示，HBeAg的下降率按年龄（OR = 0.93; CI：0.89-0.97; P <0.01），增加的速度C基因型的患者（OR = 20.5; CI：3.3-129; P <0.01）。间未经治疗的患者的HBeAg率也显著由年龄下降（OR = 0.90（0.85：0.95; P <0.0001），而率既B基因型中增加和C的患者（OR = 7.5; CI：1.8-30.5; P < 0.01和OR = 12.2; CI：。3.2-46.6; P <0.001），在调整了年龄，性别，基因型和HBeAg加重肝脏病变患病时没有显著的变化中发现HBV DNA水平中的任何两组是，无关的治疗状态，相关的年龄和性别为男性，但不向任何基因型。结论在本研究人群中，基因型B和C被发现具有较高的HBeAg率相关联，但不与增加的肝脏病理。